In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An additional advantage from the public health point of view is high safety compared to animal systems, which is important for vaccine production: there are no known plant pathogens capable of replicating in animals, and in humans in particular. A particular antigen or a protein has to be expressed in a plant using one of many available platforms; this antigen/protein subsequently needs to be purified or processed, and later formulated into a vaccine or a therapeutic; these need to be delivered to a human or animal body via an appropriate route. Naturally, all these vaccines and therapeutics must be subjected to regulatory approvals prior to their use. Thus, the challenge is to adapt plant-based platforms for production of cost-efficient biomedicals that can be approved by FDA for use as vaccine components or therapeutics which will be competitive against existing vaccines and drugs.
This volume attempts to address the entire spectrum of challenges facing the nascent field of plant-based biomedicals, from the selection of an appropriate production platform to specific methods of downstream processing and regulatory approval issues.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 4EVAQL9IMG
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An additional advantage from the public health point of view is high safety compared to animal systems, which is important for vaccine production: there are no known plant pathogens capable of replicating in animals, and in humans in particular. A particular antigen or a protein has to be expressed in a plant using one of many available platforms; this antigen/protein subsequently needs to be purified or processed, and later formulated into a vaccine or a therapeutic; these need to be delivered to a human or animal body via an appropriate route. Naturally, all these vaccines and therapeutics must be subjected to regulatory approvals prior to their use. Thus, the challenge is to adapt plant-based platforms for production of cost-efficient biomedicals that can be approved by FDA for use as vaccine components or therapeutics which will be competitive against existing vaccines and drugs.This volume attempts to address the entire spectrum of challenges facing the nascent field of plant-based biomedicals, from the selection of an appropriate production platform to specific methods of downstream processing and regulatory approval issues. 132 pp. Englisch. N° de réf. du vendeur 9783642089831
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An ad. N° de réf. du vendeur 5048009
Quantité disponible : Plus de 20 disponibles
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Plant-produced Microbial Vaccines | Alexander V. Karasev | Taschenbuch | Current Topics in Microbiology and Immunology | x | Englisch | 2010 | Springer | EAN 9783642089831 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand. N° de réf. du vendeur 106954466
Quantité disponible : 5 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. x + 120. N° de réf. du vendeur 2614419219
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An additional advantage from the public health point of view is high safety compared to animal systems, which is important for vaccine production: there are no known plant pathogens capable of replicating in animals, and in humans in particular. A particular antigen or a protein has to be expressed in a plant using one of many available platforms; this antigen/protein subsequently needs to be purified or processed, and later formulated into a vaccine or a therapeutic; these need to be delivered to a human or animal body via an appropriate route. Naturally, all these vaccines and therapeutics must be subjected to regulatory approvals prior to their use. Thus, the challenge is to adapt plant-based platforms for production of cost-efficient biomedicals that can be approved by FDA for use as vaccine components or therapeutics which will be competitive against existing vaccines and drugs. This volume attempts to address the entire spectrum of challenges facing the nascent field of plant-based biomedicals, from the selection of an appropriate production platform to specific methods of downstream processing and regulatory approval issues.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 132 pp. Englisch. N° de réf. du vendeur 9783642089831
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An additional advantage from the public health point of view is high safety compared to animal systems, which is important for vaccine production: there are no known plant pathogens capable of replicating in animals, and in humans in particular. A particular antigen or a protein has to be expressed in a plant using one of many available platforms; this antigen/protein subsequently needs to be purified or processed, and later formulated into a vaccine or a therapeutic; these need to be delivered to a human or animal body via an appropriate route. Naturally, all these vaccines and therapeutics must be subjected to regulatory approvals prior to their use. Thus, the challenge is to adapt plant-based platforms for production of cost-efficient biomedicals that can be approved by FDA for use as vaccine components or therapeutics which will be competitive against existing vaccines and drugs.This volume attempts to address the entire spectrum of challenges facing the nascent field of plant-based biomedicals, from the selection of an appropriate production platform to specific methods of downstream processing and regulatory approval issues. N° de réf. du vendeur 9783642089831
Quantité disponible : 1 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. x + 120 26 Illus. (10 Col.). N° de réf. du vendeur 11254476
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. x + 120. N° de réf. du vendeur 1814419225
Quantité disponible : 4 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. reprint edition. 130 pages. 9.25x6.10x0.31 inches. In Stock. N° de réf. du vendeur 3642089836
Quantité disponible : 1 disponible(s)